𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease

✍ Scribed by Yosef A. Berlow; William M. Wells; James M. Ellison; Young Hoon Sung; Perry F. Renshaw; David G. Harper

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
284 KB
Volume
25
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To investigate the association of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) and magnetic resonance imaging (MRI) measures of brain atrophy and white matter hyperintensities (WMH).

Methods

Thirty‐seven patients with probable AD received the Neuropsychiatric Inventory (NPI), the Mini Mental Status Exam (MMSE), and an MRI scan as part of their initial evaluation at the Outpatient Memory Diagnostic Clinic at McLean Hospital. MRI‐based volumetric measurements of whole brain atrophy, hippocampal volumes, and WMH were obtained. Analysis of covariance models, using age as a covariate and the presence of specific BPSD as independent variables, were used to test for differences in whole brain volumes, hippocampal volumes and WMH volumes.

Results

Increased WMH were associated with symptoms of anxiety, aberrant motor behavior, and night time disturbance, while symptoms of disinhibition were linked to lower WMH volume. No associations were found for whole brain or hippocampal volumes and BPSD.

Conclusions

These findings suggest that white matter changes are associated with the presence of BPSD in AD. Copyright Β© 2009 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

Visual rating of white matter hyperinten
Visual rating of white matter hyperintensities in Parkinson's disease
✍ Mona K. Beyer; Dag Aarsland; Ole Jacob Greve; Jan P. Larsen πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 1 views

## Abstract Dementia is a common complication of Parkinson's disease (PD), but the cause is incompletely understood. In previous studies, dementia has been associated with an increase in hyperintense lesions in the cerebral white matter. The aim of this study was to explore whether white matter hyp

Brain atrophy and white matter hyperinte
Brain atrophy and white matter hyperintensities in early Parkinson's disease
✍ Turi O. Dalaker; Jan P. Larsen; Niels Bergsland; Mona K. Beyer; Guido Alves; Mic πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 202 KB πŸ‘ 1 views

## Abstract The purpose of this research was to examine the extent of global brain atrophy and white matter hyperintensities (WMH) in early Parkinson's disease (PD) compared to normal controls (NC), to explore the relationship between the MRI variables and cognition in PD. In this multicenter study

White matter tract integrity in aging an
White matter tract integrity in aging and Alzheimer's disease
✍ Jessica S. Damoiseaux; Stephen M. Smith; Menno P. Witter; Ernesto J. Sanz-Arigit πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 220 KB πŸ‘ 1 views

## Abstract The pattern of degenerative changes in the brain white matter (WM) in aging, mild cognitive impairment (MCI), and Alzheimer's disease (AD) has been under debate. Methods of image analysis are an important factor affecting the outcomes of various studies. Here we used diffusion tensor im

Behavioural and psychological symptoms a
Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease
✍ Salka S. Staekenborg; Freek Gillissen; Rolinka Romkes; Yolande A. L. Pijnenburg; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 101 KB πŸ‘ 2 views

## Abstract ## Background The neuropathology of behavioural and psychological symptoms is much less understood than the neuropathology of cognitive impairment in AD. On MRI, medial temporal lobe atrophy (MTA) is presumed to reflect Alzheimer‐ type pathology. White matter hyperintensities (WMH) are

Hypertension, white matter change and re
Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease
✍ Peter J. Connelly; Neil P. Prentice; Kenneth G. Fowler πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 1 views

Background Cholinesterase inhibitors are used to treat mild to moderate Alzheimer's disease. Their role in patients with concurrent cerebrovascular disease has been less well studied, and the influence of vascular risk factors on response to treatment is uncertain. We investigated the effect of hype